Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16322044 | 1.00 | LMNA (0.41) | LMNACXCR2ADRB2ADRB1CXCR1 | |
| SCHEMBL12129521 | 0.85 | PTGS2 (0.49) | LMNACXCR2ADRB2ADRB1CXCR1 | |
| SCHEMBL28065141 | 0.85 | PTGS2 (0.49) | LMNACXCR2ADRB2ADRB1CXCR1 | |
| SCHEMBL25167208 | 0.83 | EPHX1 (0.47) | LMNAADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL966639 | 0.83 | EPHX1 (0.47) | LMNAADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL12920472 | 0.83 | PGR (0.39) | LMNACXCR2ADRB2ADRB1CXCR1 | |
| SCHEMBL966044 | 0.82 | CA12 (0.39) | LMNACXCR2ADRB2ADRB1CXCR1 | |
| SCHEMBL28065142 | 0.82 | CA12 (0.39) | LMNACXCR2ADRB2ADRB1CXCR1 | |
| SCHEMBL963917 | 0.82 | EPHX1 (0.46) | LMNAADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL30448999 | 0.82 | LMNA (0.40) | LMNAADRB2ADRB1ADRB3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024329-B1 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2013-07-31 | — | — | EP | claimed |
| US-7868046-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | DOMPE' PHA.R.MA S.P.A. (IT) | 2011-01-11 | — | — | US | claimed |
| US-20100152256-A1 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | DOMPE' PHA.R.MA S.P.A. (IT) | 2010-06-17 | — | — | US | claimed |
| US-7652169-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | Dompe' Pha. R. Ma S.p.A. (IT) | 2010-01-26 | — | — | US | claimed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | claimed |
| EP-2024329-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-02-18 | — | — | EP | claimed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | claimed |
| US-11453715-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | NEW YORK UNIVERSITY (US) | 2022-09-27 | — | — | US | disclosed |
| EP-3848046-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MUTATED LEUKOCIDIN E | New York University (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210009664-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | UNIV NEW YORK (US) | 2021-01-14 | — | — | US | disclosed |
| EP-3441474-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MUTATED LEUKOCIDIN E | UNIV NEW YORK (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10301378-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | NEW YORK UNIVERSITY (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3441474-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MUTATED LEUKOCIDIN E | New York University (US) | 2019-02-13 | — | — | EP | disclosed |
| US-7652169-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | Dompe' Pha. R. Ma S.p.A. (IT) | 2010-01-26 | — | — | US | disclosed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| EP-2024329-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453715-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | CXCR1, CXCR2, CXCR5 | LMNA 4124/4885CXCR2 2/4885ADRB2 3402/4885 |
| US-20100152256-A1 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | CCR2, CXCR2, CXCR4 | LMNA 3868/4885CXCR2 2/4885ADRB2 750/4885 |
| US-10301378-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | CXCR1, CXCR2, CXCR5 | LMNA 4124/4885CXCR2 2/4885ADRB2 3402/4885 |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | CCR2, CXCR2, CXCR3 | LMNA 3833/4885CXCR2 2/4885ADRB2 1127/4885 |
| US-20210009664-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | LMNA 4124/4885CXCR2 2/4885ADRB2 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.